张晓进，博士，教授，博士生导师，理学院副院长、化学系主任（兼）。牛津大学访问学者。国家优秀青年科学基金获得者，江苏省杰青、优青基金获得者，江苏省“333高层次人才培养工程”第二层次（中青年科技领军人才）。

长期从事创新药物研发及药物化学研究，主持国家及江苏省自然科学基金项目十余项，承担多项校企联合攻关项目。以通讯作者在Journal of the American Chemical Society、Angewandte Chemie International Edition (3)、Journal of Medicinal Chemistry (14)、European Journal of Medicinal Chemistry (12)、Chinese Chemical Letters、Chemical Science、Chemical Communications、Organic Letters等国际刊物发表论文70余篇；已授权中国、美国等国内外发明专利20余项，其中2个候选新药相关专利实现技术成果转化。曾获国家科技进步奖二等奖、教育部自然科学奖一等奖、江苏省科学技术一等奖、中国药学会青年药物化学奖。作为主要负责人设计研发的化药1类抗贫血新药在中国进入临床试验。

主要研究方向：聚焦“细胞氧感知通路”的靶向创新药物研发，化学创新驱动的新药发现

研究生招生专业：药物化学（学博）、药学（专博）、药物化学（学硕）、化学（学硕）、药学（专硕）

实验室常用技术手段：计算机辅助药物设计（CADD）、人工智能驱动的药物设计（AIDD）、量子化学计算；化学合成与结构表征；靶标水平活性测试方法构建；体内外PK/PD及安全性评价；临床前成药性评价等

联系方式：zxj@cpu.edu.cn  地址：江宁校区化学楼C505

近年代表性论文:

1.      Light-induced, lysine-targeting irreversible covalent inhibition of the human oxygen sensing hydroxylase factor inhibiting HIF (FIH). Yue Wu, Zhihong Li, Samanpreet Kaur, Zewei Zhang, Jie Yue, Anthony Tumber, Haoshu Zhang, Zhe Song, Peiyao Yang, Ying Dong, Fulai Yang, Xiang Li, Christopher J. Schofield, Xiaojin Zhang. Journal of the American Chemical Society 2025, 147 (21), 17871–17879 (IF=14.5) https://doi.org/10.1021/jacs.5c01935

2.      Discovery of ZG-2305, an orally bioavailable factor inhibiting HIF inhibitor for the treatment of obesity and fatty liver disease. Yue Wu, Zewei Zhang, Haiping Cai, Weiqing Zhang, Linjian Zhang, Zhihong Li, Le Yang, Yafen Chen, Thomas Corner, Zhe Song, Jie Yue, Fulai Yang, Xiang Li, Christopher J. Schofield, Xiaojin Zhang. Journal of Medicinal Chemistry 2025, 67 (16), 14668–14691 https://doi.org/10.1021/acs.jmedchem.4c01698

Front Cover: https://pubs.acs.org/toc/jmcmar/68/1

3.      3-(Arylamido)pyrazolopyridine HIF-2α agonists and a codrug strategy with prolyl hydroxylase inhibition for synergistic treatment of renal anemia. Yinli Gao, Qingyun Yang, Simeng Liu, Jiaming Liu, Liwei Chen, Xiaoqian Bao, Linjian Zhang, Le Yang, Fulai Yang, Xiang Li, Yue Wu, Xiaojin Zhang. Journal of Medicinal Chemistry 2025, 68 (23), 25569–25589 https://doi.org/10.1021/acs.jmedchem.5c02719

4.      Machine-learning-driven discovery of N-phenylbenzenesulfonamides as a novel chemotype for lactate dehydrogenase A inhibition with anti-pancreatic cancer activity. Qijie Gong, Ying Dong, Jiaqi Liang, Jian Zhou, Guowei Zhang, Le Yang, Tiande Bing, Fidiniaina Rina Juliana, Ziyuan Zhu, Yue Wu, Fulai Yang, Xiang Li, Xiaojin Zhang. Journal of Medicinal Chemistry 2025, 68 (14), 14384–14404 https://doi.org/10.1021/acs.jmedchem.5c00359

5.      A small-molecule inhibitor of factor inhibiting HIF binding to a tyrosine-flip pocket for the treatment of obesity. Yue Wu, Yafen Chen, Thomas Corner, Yu Nakashima, Eidarus Salah, Zhihong Li, Linjian Zhang, Le Yang, Anthony Tumber, Zhuoli Sun, Yukang Wen, Ailin Zhong, Fulai Yang, Xiang Li, Zhihong Zhang, Christopher J. Schofield, Xiaojin Zhang. Angewandte Chemie International Edition 2024, 63 (40), e202410438 (IF=16.1) https://doi.org/10.1002/anie.202410438

Cover: https://onlinelibrary.wiley.com/doi/10.1002/anie.202414504

6.      Discovery of a potent and orally bioavailable xanthine oxidase/urate transporter 1 dual inhibitor as a potential treatment for hyperuricemia and gout. Xinye Yang, Yong Li, Shengqiang Pan, Facheng Ma, Hong Chen, Jinhui Deng, Jie Yue, Qijie Gong, Mi Zheng, Ying Zeng, Jing Li, Yingjun Zhang, Xiaojun Wang, Xiaojin Zhang. Journal of Medicinal Chemistry 2024, 67 (16), 14668–14691 https://doi.org/10.1021/acs.jmedchem.4c01480

7.      Preferred conformation-guided discovery of potent and orally active HIF prolyl hydroxylase 2 inhibitors for the treatment of anemia. Yue Wu, Linjian Zhang, Zhuoli Sun, Xusheng Qiu, Yafen Chen, Kaijun Su, Le Yang, Zhongqiu Du, Ying Dong, Fulai Yang, Xiang Li, Xiaojin Zhang. Journal of Medicinal Chemistry 2023, 66 (13), 8545–8563 https://doi.org/10.1021/acs.jmedchem.3c00231

8.      In situ inhibitor synthesis and screening by fluorescence polarization: an efficient approach for accelerating drug discovery. Zhihong Li, Yue Wu, Shuai Zhen, Kaijun Su, Linjian Zhang, Fulai Yang, Michael A. McDonough, Christopher J. Schofield, Xiaojin Zhang. Angewandte Chemie International Edition 2022, 61 (45), e202211510 (IF=16.8) https://doi.org/10.1002/anie.202211510

9.      A carbon-carbon bond cleavage–based prodrug activation strategy applied to β-lapachone for cancer-specific targeting. Qijie Gong, Xiang Li, Tian Li, Xingsen Wu, Jiabao Hu, Fulai Yang, Xiaojin Zhang. Angewandte Chemie International Edition 2022, 61 (40), e202210001 (IF=16.8) https://doi.org/10.1002/anie.202210001

10.   Discovery of a potent and orally bioavailable hypoxia-inducible factor 2α (HIF-2α) agonist and its synergistic therapy with prolyl hydroxylase inhibitors for the treatment of renal anemia. Yancheng Yu, Fulai Yang, Quanwei Yu, Simeng Liu, Chenyang Wu, Kaijun Su, Le Yang, Xiaoqian Bao, Zhihong Li, Xiang Li, Xiaojin Zhang. Journal of Medicinal Chemistry 2021, 64 (23), 17384–17402 (cover) https://doi.org/10.1021/acs.jmedchem.1c01479

11.   Inhibition of the oxygen-sensing asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor: A potential hypoxia response modulating strategy. Yue Wu, Zhihong Li, Michael A. McDonough, Christopher J. Schofield, Xiaojin Zhang. Journal of Medicinal Chemistry 2021, 64 (11), 7189–7209 https://doi.org/10.1021/acs.jmedchem.1c00415

12.   Reactive oxygen species (ROS)-responsive prodrugs, probes, and theranostic prodrugs: applications in the ROS-related diseases. Pengfei Wang, Qijie Gong, Jiabo Hu, Xiang Li, Xiaojin Zhang. Journal of Medicinal Chemistry 2021, 64 (1), 298–325 https://doi.org/10.1021/acs.jmedchem.0c01704

13.   Discovery of clinical candidate (5-(3-(4-chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an orally bioavailable prolyl hydroxylase inhibitor for the treatment of anemia. Xiaojin Zhang,* Yonghua Lei, Tianhan Hu, Yue Wu, Zhihong Li, Zhensheng Jiang, Changyong Yang, Lianshan Zhang, Qidong You.* Journal of Medicinal Chemistry 2020, 63 (17), 10045–10060 https://doi.org/10.1021/acs.jmedchem.0c01161

14.   Photoactivatable prolyl hydroxylase 2 inhibitors for stabilizing the hypoxia-inducible factor with light. Zhihong Li, Kaijun Su, Zhensheng Jiang, Yancheng Yu, Qidong You, Xiaojin Zhang. Journal of Medicinal Chemistry 2019, 62 (16), 7583–7588 https://doi.org/10.1021/acs.jmedchem.9b00688

Front Cover: https://pubs.acs.org/toc/jmcmar/62/16

15.   Small-molecule modulators of the hypoxia-inducible factor pathway: Development and therapeutic applications. Zhihong Li, Qidong You, Xiaojin Zhang. Journal of Medicinal Chemistry 2019, 62 (12), 5725–5749 https://doi.org/10.1021/acs.jmedchem.8b01596

16.   Discovery of nonquinone substrates for NAD(P)H: quinone oxidoreductase 1 (NQO1) as effective intracellular ROS generators for the treatment of drug-resistant non-small cell lung cancer. Xingsen Wu, Xiang Li, Zhihong Li, Yancheng Yu, Qidong You, Xiaojin Zhang. Journal of Medicinal Chemistry 2018, 61 (24), 11280–11297 (cover) https://doi.org/10.1021/acs.jmedchem.8b01424

17.   Click chemistry–based discovery of [3-hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as orally active hypoxia inducing factor prolyl hydroxylase inhibitors with favorable safety profiles for the treatment of anemia. Yue Wu, Zhensheng Jiang, Zhihong Li, Jing Gu, Qidong You, Xiaojin Zhang. Journal of Medicinal Chemistry 2018, 61 (12), 5332–5349 https://doi.org/10.1021/acs.jmedchem.8b00549